Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: Resolved and unresolved issues

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 1, 2014, Pages 26-30

  Liu, Chun Jen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Dual infection; HBsAg clearance; Hepatitis B virus; Hepatitis C virus; Interferon; Pegylated interferon; Ribavirin; Sustained virological response

Indexed keywords

ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HOST FACTOR; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; RIBAVIRIN; VIRUS DNA;

FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONG TERM CARE; MIXED INFECTION; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; TAIWAN; TREATMENT OUTCOME; VIRUS REACTIVATION;

DUAL INFECTION; HBSAG CLEARANCE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; INTERFERON; PEGYLATED INTERFERON; RIBAVIRIN; SUSTAINED VIROLOGICAL RESPONSE;

ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; COINFECTION; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; RECOMBINANT PROTEINS; RIBAVIRIN; VIRUS ACTIVATION;

EID: 84897653996     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12421     Document Type: Review

References (28)

1. Liu CJ, Liou JM, Chen DS, Chen PJ. Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections. J. Formos. Med. Assoc. 2005; 104: 783-791.
2. Liu CJ, Chen PJ, Chen DS. Dual chronic hepatitis B virus and hepatitis C virus infection. Hepatol. Int. 2009; 3: 517-525.
3. Chen DS. Fighting against viral hepatitis: lessons from Taiwan. Hepatology 2011; 54: 381-392.
4. Sagnelli E, Coppola N, Messina V etal. HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. Hepatology 2002; 36: 1285-1291.
5. Liaw YF, Chen YC, Sheen IS, Chien RN, Yeh CT, Chu CM. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology 2004; 126: 1024-1029.
6. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int. J. Cancer 1998; 75: 347-354.
7. Huang YT, Jen CL, Yang HI etal. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. J. Clin. Oncol. 2011; 29: 3643-3650.
8. Liu CJ, Chuang WL, Lee CM etal. An open label, comparative, multicenter study of peginterferon alfa-2a plus ribavirin in the treatment of patients with chronic hepatitis C/hepatitis B co-infection versus those with chronic hepatitis C monoinfection. Gastroenterology 2009; 136: 496-504.
9. Yu ML, Lee CM, Chen CL etal. Sustained HCV clearance and increased HBsAg seroclearance in patients with dual chronic hepatitis C and B during post-treatment follow-up. Hepatology 2013; 57: 2135-2142.
10. Liu CJ, Chu YT, Shau WY, Kuo RNC, Chen PJ, Lai MS. Treatment of patients with dual hepatitis C and B by peginterferon alfa and ribavirin reduced risk of hepatocellular carcinoma and mortality. Gut 2013. [Epub ahead of print].
11. Raimondo G, Brunetto MR, Pontisso P etal. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-co-infected patients. Hepatology 2006; 43: 100-107.
12. Nguyen LH, Ko S, Wong SS etal. Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection. Hepatology 2011; 53: 1839-1845.
13. Villa E, Grottola A, Buttafoco P etal. High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial. Am. J. Gastroenterol. 2001; 96: 2973-2977.
14. Liu CJ, Chen PJ, Lai MY, Kao JH, Jeng YM, Chen DS. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology 2003; 37: 568-576.
15. Chuang WL, Dai CY, Chang WY etal. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy. Antivir. Ther. 2005; 10: 125-133.
16. Hung CH, Lee CM, Lu SN etal. Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection. J. Gastroenterol. Hepatol. 2005; 20: 727-732.
17. Potthoff A, Wedemeyer H, Boecher WO etal. The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha 2b and ribavirin in patients with HBV/HCV co-infection. J. Hepatol. 2008; 49: 688-694.
18. Kim YJ, Lee JW, Kim YS etal. Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus. Korean J. Hepatol. 2011; 17: 199-205.
19. Yeh ML, Hung CH, Huang JF etal. Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses. PLoS One 2011; 6: e20752.
20. Aghemo A, Colombo M. Treatment of patients with dual hepatitis B and C: a step in the right direction. Gut 2013. doi: 10.1136/gutjnl-2013-305115. [Epub ahead of print].
21. Yu ML, Lee CM, Chuang WL etal. HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. J. Infect. Dis. 2010; 202: 86-92.
22. Cheng HR, Liu CJ, Tseng TC etal. Host genetic factors affecting spontaneous HBsAg seroclearance in chronic hepatitis B patients. PLoS One 2013; 8: e53008.
23. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J. Hepatol. 2011; 55: 245-264.
24. Omata M, Kanda T, Yu ML etal. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol. Int. 2012; 6: 409-435.
25. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J. Hepatol. 2012; 57: 167-185.
26. Liaw YF, Kao JH, Piratvisuth T etal. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol. Int. 2012; 6: 531-561.
27. Marrone A, Zampino R, D'Onofrio M, Ricciotti R, Ruggiero G, Utili R. Combined interferon plus lamivudine treatment in young patients with dual HBV (HBeAg positive) and HCV chronic infection. J. Hepatol. 2004; 41: 1064-1065.
28. Coppola N, Stanzione M, Messina V etal. Tolerability and efficacy of anti-HBV nucleos(t)ide analogues in HBV-DNA-positive cirrhotic patients with HBV/HCV dual infection. J. Viral Hepat. 2012; 19: 890-896.